PFIZER ONCOLOGY PRESS KIT
PLEASE NOTE: All assets on this page are intended for use by U.S. media professionals only.
Over the past decade Pfizer Oncology has taken bold new approaches to translate scientific research into effective medicines for people living with cancer. Our portfolio of 22 cancer medicines reached over 568,000 people living with more than 30 types of cancer in 2019, and is backed by important breakthrough treatments for people with breast, prostate, kidney and lung cancers, as well as leukemia and melanoma.
For the latest information on our growing pipeline, product portfolio and collaborations with the broader cancer community, visit this page periodically for updates.
PFIZER AT THE VIRTUAL SCIENTIFIC PROGRAM OF THE 2020 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
Pfizer will present data across its industry-leading oncology portfolio, covering multiple tumor types and mechanisms of action. This year, we highlight scientific advancements for people living with cancer with presentations spanning 18 approved and investigational medicines being studied in over 17 cancer types.
Please visit the links below for information on Pfizer Oncology being showcased at the ASCO20 Virtual Scientific Program.
- Leadership Audiogram
- The Virtual Scientific Program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting Curtain Raiser
- To learn more about Pfizer Oncology’s data presentations at the Virtual Scientific Program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, click here
PFIZER ABSTRACT PLAIN LANGUAGE SUMMARIES (APLS) AT THE VIRTUAL SCIENTIFIC PROGRAM OF THE 2020 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
To help interested non-scientists better understand the latest research, we are developing summaries in plain language for Pfizer research results presented at medical conferences. We call these “abstract plain language summaries” (APLS).